U.S. biotechnology company Luminex Corporation announced that it has agreed to acquire life science and high technology company MilliporeSigma's flow cytometry portfolio for $75 million, consisting of approximately $69.9 million to be paid under a stock and asset purchase agreement and approximately $5.1 million in committed inventory purchases.
MilliporeSigma's flow cytometry portfolio includes Amnis, the family of imaging flow cytometry products for cell-based analysis, as well as their Guava portfolio of products, which are economical, high-performance systems based on microcapillary technologies.
The acquisition expands Luminex's existing offering of flow-based detection systems, which is centered around its innovative xMAP multiplexing technology, with more than 15,000 xMAP systems sold worldwide.
Luminex said that this move allows it to expand its footprint into the multi-billion dollar flow cytometry market. The company expects this deal to provide the opportunity for meaningful growth. The deal is expected to close by the end of 2018, and to contribute $40 million to $50 million in revenue to the company in 2019.